Skip to main content

Table 2 Association between ACEI/ARB therapy and one-year outcomes in AF patients with hypertension

From: Impact of renin–angiotensin–aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension

Outcomes Total ACEI/ARB no ACEI/ARB P value Univariable analysis Multivariable analysis*
(n = 1110) (n = 574) (n = 536) HR (95%CI) P value HR (95% CI) P value
All-cause death 169 [15.2%] 72 [12.5%] 97 [18.1%] 0.010 0.658 (0.485–0.893) 0.007 0.605 (0.431–0.849) 0.004
Cardiovascular death 100 [9.0%] 48 [8.4%] 52 [9.7%] 0.436 0.778 (0.521–1.162) 0.220 0.585 (0.372–0.921) 0.020
Stroke 98 [8.8%] 46 [8.0%] 52 [9.7%] 0.322 3.391 (0.353–32.602) 0.290 0.721 (0.468–1.111) 0.138
MAEs 255 [23.0%] 112 [19.5%] 143 [24.8%] 0.005 0.692 (0.540–0.886) 0.004 0.651 (0.496–0.855) 0.002
  1. *Adjusted for age, body mass index, heart rate, heart failure, significant valvular disease, rheumatic heart disease, prior stroke/transient ischemic attack, dementia, chronic obstructive pulmonary disease, diuretic, warfarin, CHADS2 score ≥ 2, statins, beta-blockers, aspirin, digoxin, and amiodarone